NZ286752A - Stable injectable composition of endecticides - Google Patents
Stable injectable composition of endecticidesInfo
- Publication number
- NZ286752A NZ286752A NZ286752A NZ28675296A NZ286752A NZ 286752 A NZ286752 A NZ 286752A NZ 286752 A NZ286752 A NZ 286752A NZ 28675296 A NZ28675296 A NZ 28675296A NZ 286752 A NZ286752 A NZ 286752A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- oil
- oils
- group
- chosen
- Prior art date
Links
Description
New Zealand Paient Spedficaiion for Paient Number £86752
QU&S!
ft'"**
6 7
9 0 0
.<*
3*«M
y
U
1
&1 ^
Patents Form # 5
NEW ZEALAND Patents Act 1953 COMPLETE SPECIFICATION
AFTER PROVISIONAL #: DATED:
TITLE:
286752/299093
June 1996/30 July 1996 Injectable Compositions
We, Ashmoiit Holdings Limited
Address: 48 Diana Drive, Glenfield, Auckland, New Zealand Nationality: New Zealand do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the following statement:
PF05.JWP
FEE CODE 1050
or on
TECHNICAL FIELD OF THE INVENTION
This invention relates to novel compositions of macrolide avermectin and milbemycin endecticides with an immunising agent and in particular it relates to a stable injectable composition for use with warm-blooded animals, in particular ruminants.
The use of a combination of an parasitic agent and immunising agent as a single injectable formulation offers advantages both in time and cost saving to the farmer.
BACKGROUND
New Zealand Patent Nos. 191413 and 193807 of ICI Tasman Limited disclose water based formulations of D, L-tetramisole and clostridial vaccine in the treatment of helminthiasis and 10 clostridial diseases in warm-blooded animals. Both D, L-tetramisole and the clostridial vaccine are water soluble hence a combination of the two is straight forward. What was surprising was that the clostridial vaccine remained effective at a pH lower than 6.0 and that the combination improved the immune response in ruminants, though not '~i other animals.
These aqueous formulations commonly used an adjuvant such as alum or alum hydroxide to 15 enhance the effect of the antigen. Such adjuvants are usually included in the formulation as an aqueous suspensions. The vaccines can then be readily mixed with water based anthelmintic formulations.
Since the use of D, L-tetramisole and more particularly the L-isomer levamisole, there have been a number of other potent antiparasitic macrocyclic lactone compounds such as the 20 avermectins, ivermectin, doramectin, abamectin, milbemycin, moxidectin used in the 8462scsl.696//S
treatment of diseases in warm blooded animals. These later parasiticides are insoluble in water which creates difficulties in formulating stable injectable compositions. However, the compounds have the advantage that they are active against internal and external parasites in domestic animals.
Formulations are therefore based on co-solvent systems or aqueous solvent systems utilising a water-soluble solvent with one or more wetting agents. Water soluble solvents mix readily with traditional aqueous adjuvant systems to form combinations of anthelmintics and vaccines. This is not the case with oil based (non-aqueous) systems.
It is an object of the invention to provide an improved injectable composition combining a parasitic agent and an antigen or at least one that provides the public with a useful choice.
STATEMENT OF INVENTION
It has been surprisingly discovered that non-aqueous anthelmintics can be combined with an antigen using a liquid such as an oil as an adjuvant and carrier to give a stable formulation 15 that can be safely injected into warm blooded animals including cattle and sheep.
In one aspect the invention comprises a stable injectable composition comprising a nonaqueous parasitic agent in a therapeutically effect amount and an antigen in combination with a liquid carrier that also acts as an adjuvant for use with warm blooded animals.
OBJECT
8462SCS2.897//S
752
n a &
Preferably the non-aqueous parasitic agent is a macrolide compound selected from group comprising avermectin, ivermectin, doramectin, abamectin, milbemycin and moxidectin, present in from 0.05 to 10% w/v.
More preferably the non-aqueous parasitic agent is chosen from the group comprising 5 abamectin, ivermectin, moxidectin and doramectin.
Preferably, the carrier is an oil, either a vegetable oil such as sesame oil, saponine oil, soya bean oil, and corn oil or a mineral adjuvant oil, such as paraffin oil, or purified derivatives of vegetable or mineral oils, such as quiala, which is suitable for injection into animals or a mixture thereof. The oil acts as an adjuvant for the immunising agent and may also act as a 10 solvent for the anthelmintic. The oil also extends the action of the parasitic agent.
Additionally, the composition may further contain an oil soluble solvent. The oil soluble solvent is chosen from the group comprising alcohols having four or more carbon atoms for example benzyl alcohol, ethylbenzyl alcohol, phenethyl alcohol and other aromatic monohydric alcohols.
Preferably the alcohol is present in the range from 10-50 wlv%.
The antigen is incorporated into the composition by emulsifying it in a suitable emulsion agent, for example sorbiten oleate (Span 80™ or Liposorb 80™). Other suitable emulsion agents may also be used. The emulsifier is present in the range of from 5-50 w/v%.
8462scsl.696//S
Antigens suitable to be used in the compositions include antigens derived from bacterial and viral pathogens of warm-blooded animals. Preferably the antigen is chosen from the group comprising antigens derived from and toxins of clostridial diseases including Clostridium septicum, Clostridium tetani, Clostridium chauvoei, Clostridium novyi, Clostridium sordelli and Clostridium haemolytica. Other possible antigens include Pasteurella, Pasteurella maltocida and Corynebacterium pseudotuberculosis and viral antigens for Infectious Bovine Rhinotracheitis, Bovine Viral Diarrhoea and Parainfluenza
In another aspect, the invention comprises a method of treating parasitic diseases and preventing viral and bacterial diseases in warm blooded animals by administration to an animal of a composition as described above.
Preferably the composition is administered to the animal by injecting the animal.
Preferably the composition is administered at the rate of 0.5-5mL/50kg bodyweight of the animal.
PREFERRED EMBODIMENTS
The present invention will be described by way of example only with reference to the following examples.
8462scsl.696//S
2£
-s_
Formulation lfoil based)
Part A
w/v%
Abamectin
1.00
Benzyl Alcohol
.0
Sesame oil
40.0.
Paraffin Oil to volume
Part B
v/v%
Part A (1% abamectin)
50.0mls
Span 80
lOgm
Vaccine to volume
100%
Formulation 2 foil based)
Part A
w/v%
Abamectin (or ivermectin)
1.13
Benzyl Alcohol
.0
Sesame Oil to volume
Part B
v/v%
Ivermectin Benzyl Alcohol Saponin Oil
8462scsl .696//S
v.J
Part A (1% abamectin)
50.0mls
Span 80
gm
Vaccine to volume
100%
Formulation 3 foii based)
Part A
w/v%
1.00 10.0
to volume
9H
-Q
Part B v/v%
Part A 50.0mls
Span 80 20 gm
Vaccine to volume
100%
Formulation 4 foil based)
Part A w/v%
Doramectin 1.13
Benzyl Alcohol 20.0
Sesame Oil to volume
PartB v/v%
Part A (1 % abamectin) 50.0mls
Liposorb 80 10 gm
Vaccine to volume
100%
Formulation 5 foil based)
Part A w/v%
Abamectin 1.13
Benzyl Alcohol 20.0
Sesame Oil to volume
PartB v/v%
Part A 50.0ml
Sorbitan Oleate lOgm
Antigen 1 4.555ml
Antigen 2 0.135ml
Antigen 3 0.870ml
8462scsl.696//S
2990
Antigen 4 Antigen 5 Benzyl Alcohol
0.933ml
4.258ml to volume
100%
Dosage rates for these formulations range from 0.5 - 5ml/50kg bodyweight of the animal.
These preparations have been shown to be stable and do not cause injury when injected to warm blooded animals. The parasitic agent and the antigen retain their activity. The formulations have a shelf life of approximately two years.
We have found that a formulation of a parasitic agent and an antigen, such as a closr idial 10 antigen, containing an oil such as sesame oil as the solvent is effective in the treatment of helminthiasis and clostridial diseases in warm blooded animals. Suprisingly, the oil also acts as an adjuvant in the composition, enhancing the activity of the vaccine and extending the parasiticide activity of the anthelmintic. Compositions that contained a traditional adjuvant such as alum and the oil stimulated the working of the vaccine to such a level that an adverse 15 reaction was produced in the animal.
ADVANTAGES
The compositions of the invention are stable and be stored for long periods of time without loss of either parasitic agent or antigen potency.
8462scsl.696//S
Claims (10)
1. A stable injectable composition comprising a non-aqueous parasitic agent in a therapeutically effect amount, chosen from the macrolide group of compounds comprising avermectin, ivermectin, doramectin, abamectin, milbemycin and moxidectin, and an antigen in combination with a liquid carrier that also acts as an adjuvant for use with warm blooded animals.
2. A composition as claimed in claim 1 wherein the non-aqueous parasitic agent is present in from 0.05-10 w/v%.
3. A composition as claimed in claim 1 or claim 2 wherein the non-aqueous parasitic agent is chosen from the group comprising abamectin, ivermectin, moxidectin and doramectin.
4. A composition as claimed in any preceding claim wherein the carrier is an oil or mixture of oils which is suitable for injection into animals and is chosen from the group comprising sesame oil, saponine oil, soya bean oil, corn oil, paraffin oils, purified derivatives of vegetable oils and mineral adjuvant oils and mixtures thereof, and wherein the carrier extends the potency of the parasitic agent
5. A composition as claimed in any preceding claim further containing an oil soluble solvent chosen from the group comprising alcohols having four or more carbon atoms and the oil soluble solvent is present in a range from 10-50 w/v%. 8462SCS2.897//S COGWATEfMJ -11 - 5S6T5Z 299033
6. A composition as claimed in any preceding claim further containing an emulsifier and the . emulsifier is present in the range of from 5-50 w/v%.
7. A composition as claimed in any preceding claim wherein the antigen is chosen from the group comprising antigens and toxins for the prevention of clostridial diseases in warm- 5 blooded animals.
8. A method of treating parasitic diseases and treating bacterial and viral diseases in non-human warm blooded animals by administration to an animal of a composition as described in any preceding claim.
9. A method as claimed in claim 8 wherein the composition is administered to the animal by 10 injecting the animal.
10. A method as claimed in claims 8 or 9 wherein the composition is administered at the rate of 0.5-5mL/50kg bodyweight of the animal. JAMES W. PIPER & CO. (NORTH SHORE) gtyD OF CLAIMS Attorneys for 15 Ashmont Holdings Limited END OF CLAIMS 8462SCS2.897//S
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ286752A NZ286752A (en) | 1996-06-05 | 1996-06-05 | Stable injectable composition of endecticides |
AT97924403T ATE252316T1 (en) | 1996-06-05 | 1997-06-05 | INJECTABLE COMPOSITIONS |
ZA9704944A ZA974944B (en) | 1996-06-05 | 1997-06-05 | Injectable compositions. |
PCT/NZ1997/000073 WO1997046204A2 (en) | 1996-06-05 | 1997-06-05 | Injectable compositions |
US09/214,260 US6214367B1 (en) | 1996-06-05 | 1997-06-05 | Injectable compositions |
EP97924403A EP0928136B1 (en) | 1996-06-05 | 1997-06-05 | Injectable compositions |
CA002259469A CA2259469A1 (en) | 1996-06-05 | 1997-06-05 | Injectable compositions |
AU29829/97A AU728221B2 (en) | 1996-06-05 | 1997-06-05 | Injectable compositions |
DE69725745T DE69725745D1 (en) | 1996-06-05 | 1997-06-05 | INJECTABLE COMPOSITIONS |
US09/788,572 US6663879B2 (en) | 1996-06-05 | 2001-02-21 | Injectable compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ286752A NZ286752A (en) | 1996-06-05 | 1996-06-05 | Stable injectable composition of endecticides |
NZ29909396 | 1996-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ286752A true NZ286752A (en) | 1997-11-24 |
Family
ID=19925879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ286752A NZ286752A (en) | 1996-06-05 | 1996-06-05 | Stable injectable composition of endecticides |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ286752A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU701413B2 (en) * | 1995-09-25 | 1999-01-28 | Merial Ltd | Anthelmintic compositions |
-
1996
- 1996-06-05 NZ NZ286752A patent/NZ286752A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU701413B2 (en) * | 1995-09-25 | 1999-01-28 | Merial Ltd | Anthelmintic compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU728221B2 (en) | Injectable compositions | |
US11701415B2 (en) | Oil-based adjuvants | |
US5989566A (en) | Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation | |
JPS60169415A (en) | Non-aqueous ivermectin prescription having improved antivermifugal activity | |
US20230100089A1 (en) | Methods and composition for induction of immune response | |
US4853372A (en) | Non-aqueous ivermectin formulation with improved antiparasitic activity | |
NZ286752A (en) | Stable injectable composition of endecticides | |
WO2000004906A1 (en) | Non-aqueous anthelmintic composition |